12:00 AM
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BAM-002: Began Phase I/II trial

Novelos Therapeutics Inc., Newton, Mass.
Product: BAM-002
Business: Cancer
Therapeutic category: Adjunct, Stem cell stimulation
Target: Hematopoietic stem...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >